GSK plc
Holding companyRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Schedule 13D/13G stakes
Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.
| Company | Schedule | Event date | Filed | Shares | % of class | Status |
|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics, Inc. | 13D/A not restated by this amendment, the earlier 13D's purpose stands | Mar 27, 2025 | 1y | 9,190,606 | 16.4% | Current |
| WVE Wave Life Sciences, Inc. | 13G/A | Sep 30, 2024 | 1y | 16,775,691 | 11.2% | Unconfirmed since Sep 30, 2024 |
A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 3 exited, below-5% or retired stakes
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 99.3%; sector active share 90.9% against the combined 13F book's sector weights.
Over time 3 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
13 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $602,220,433 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedTrimmed
Positions the filer reducedNew Positions
Positions the filer opened this quarterSold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| CRSP |
CRISPR Therapeutics AG
Healthcare
|
Held | 3,220,627 | $175,652,996 | 29.17% | |
| WVE |
Wave Life Sciences, Inc.
Healthcare
|
Held | 18,245,691 | $106,007,464 | 17.60% | |
| VIR |
Vir Biotechnology, Inc.
Healthcare
|
Held | 8,550,954 | $87,134,221 | 14.47% | |
| BNTX |
BioNTech SE
Healthcare
|
Held | 889,824 | $82,798,123 | 13.75% | |
| IDYA |
IDEAYA Biosciences, Inc.
Healthcare
|
Held | 1,333,333 | $49,693,320 | 8.25% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Held | 340,434 | $29,001,572 | 4.82% | |
| LYEL |
Lyell Immunopharma, Inc.
Healthcare
|
Held | 1,512,659 | $21,252,858 | 3.53% | |
| SPRO |
Spero Therapeutics, Inc.
Healthcare
|
Held | 9,190,606 | $20,311,239 | 3.37% | |
| NKTX |
Nkarta, Inc.
Healthcare
|
Held | 3,150,732 | $8,916,571 | 1.48% | |
| FULC |
Fulcrum Therapeutics, Inc.
Healthcare
|
Held | 1,785,714 | $6,535,713 | 1.09% | |
| BCYC |
Bicycle Therapeutics PLC
Healthcare
|
Held | 1,529,561 | $6,485,338 | 1.08% | |
| CVRX |
CVRx, Inc.
Healthcare
|
Held | 1,007,583 | $5,178,976 | 0.86% | |
| RGNX |
REGENXBIO Inc.
Healthcare
|
Held | 271,456 | $3,252,042 | 0.54% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.